TB Diagnosis Is Moving Closer to the Point of Care

Tuberculosis remains a major global diagnostic challenge. In 2024, an estimated 10.7 million people developed TB, and 1.23 million died from the disease.

At the same time, TB diagnosis is evolving.

In 2026, WHO recommended new near-point-of-care molecular tests for TB, highlighting the need to make testing faster, more accessible and closer to where patients receive care.

But in respiratory specimens, the diagnostic question is not always simply “TB or not?”

MTB and NTM can require different diagnostic considerations.

This creates a practical need for molecular testing that can identify both targets within an efficient workflow.

Cowingene MTB and NTM Detection Kit provides:

• MTB + NTM detection in one analysis
  • PCR-based molecular detection
  • LoD: 500 copies/mLfor both MTB and NTM
  • Automated testing on the NATBox mini II
  • Integrated sample preparation, nucleic acid extraction, amplification and detection
  • Single-use cartridge design to help minimize cross-contamination

From centralized laboratories to decentralized testing, molecular diagnostics are moving closer to the patient.

And the value of testing is moving beyond detection alone — toward faster, more practical and more informative molecular workflows.

Click to view the LinkedIn post

（https://www.linkedin.com/feed/update/urn:li:activity:7503650929599115264）